Evidence map›Paper›PMID 31705038›Full record

ArticleScientific reports2019

Neural oscillations during cognitive processes in an App knock-in mouse model of Alzheimer's disease pathology.

Sofia Jacob, Gethin Davies, Marijke De Bock, Bart Hermans, Cindy Wintmolders, Astrid Bottelbergs, Marianne Borgers, Clara Theunis, Bianca Van Broeck, Nikolay V Manyakov and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Sofia JacobDepartment of Neuroscience, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Gethin DaviesDepartment of Neuroscience, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Marijke De BockDepartment of Neuroscience, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Bart HermansDepartment of Neuroscience, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Cindy WintmoldersDepartment of Neuroscience, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Astrid BottelbergsDepartment of Neuroscience, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Marianne BorgersDepartment of Neuroscience, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Clara TheunisDepartment of Neuroscience, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Bianca Van BroeckDepartment of Neuroscience, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Nikolay V ManyakovDigital Phenotyping, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.ORCID http://orcid.org/0000-0001-9037-1400
Detlef BalschunBrain & Cognition, KU Leuven, Leuven, Belgium.
Wilhelmus H I M DrinkenburgDepartment of Neuroscience, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium. wdrinken@its.jnj.com.
Janssen (Belgium) · BEVIB-KU Leuven Center for Brain & Disease Research · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple animal models have been created to gain insight into Alzheimer's disease (AD) pathology. Among the most commonly used models are transgenic mice overexpressing human amyloid precursor protein (APP) with mutations linked to familial AD, resulting in the formation of amyloid β plaques, one of the pathological hallmarks observed in AD patients. However, recent evidence suggests that the overexpression of APP by itself can confound some of the reported observations. Therefore, we investigated in the present study the App

Indexed as

Disease Models, AnimalAlzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsBehavior, AnimalBrain WavesCognitionDiscrimination LearningGene Knock-In TechniquesMaleMiceMice, Inbred C57BLMice, TransgenicMutationNeuronsPlaque, AmyloidAmyloid beta-Protein Precursor

Identifiers

PMID31705038
PMCPMC6841667
OpenAlexW2987086273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.